Cargando…

Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas

Molecular biological characterization of tumors has become a pivotal procedure for glioma patient care. The aim of this study is to build conventional MRI-based radiomics model to predict genetic alterations within grade II/III gliomas attempting to implement lesion location information in the model...

Descripción completa

Detalles Bibliográficos
Autores principales: Arita, Hideyuki, Kinoshita, Manabu, Kawaguchi, Atsushi, Takahashi, Masamichi, Narita, Yoshitaka, Terakawa, Yuzo, Tsuyuguchi, Naohiro, Okita, Yoshiko, Nonaka, Masahiro, Moriuchi, Shusuke, Takagaki, Masatoshi, Fujimoto, Yasunori, Fukai, Junya, Izumoto, Shuichi, Ishibashi, Kenichi, Nakajima, Yoshikazu, Shofuda, Tomoko, Kanematsu, Daisuke, Yoshioka, Ema, Kodama, Yoshinori, Mano, Masayuki, Mori, Kanji, Ichimura, Koichi, Kanemura, Yonehiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078954/
https://www.ncbi.nlm.nih.gov/pubmed/30082856
http://dx.doi.org/10.1038/s41598-018-30273-4
Descripción
Sumario:Molecular biological characterization of tumors has become a pivotal procedure for glioma patient care. The aim of this study is to build conventional MRI-based radiomics model to predict genetic alterations within grade II/III gliomas attempting to implement lesion location information in the model to improve diagnostic accuracy. One-hundred and ninety-nine grade II/III gliomas patients were enrolled. Three molecular subtypes were identified: IDH1/2-mutant, IDH1/2-mutant with TERT promoter mutation, and IDH-wild type. A total of 109 radiomics features from 169 MRI datasets and location information from 199 datasets were extracted. Prediction modeling for genetic alteration was trained via LASSO regression for 111 datasets and validated by the remaining 58 datasets. IDH mutation was detected with an accuracy of 0.82 for the training set and 0.83 for the validation set without lesion location information. Diagnostic accuracy improved to 0.85 for the training set and 0.87 for the validation set when lesion location information was implemented. Diagnostic accuracy for predicting 3 molecular subtypes of grade II/III gliomas was 0.74 for the training set and 0.56 for the validation set with lesion location information implemented. Conventional MRI-based radiomics is one of the most promising strategies that may lead to a non-invasive diagnostic technique for molecular characterization of grade II/III gliomas.